GlassScriptPhysician profile
Larry A Hollar
NPI 1417038738
$856.80
in general payments reported to CMS, 2019-2025
17 companies · $807 in 2025
The $807 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $0.79 · 2024: $48.82 · 2025: $807.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $856 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $856.01 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $236.66 | 2025 | |
| Janssen Biotech, INC. | $79.29 | 2025 | Tremfya |
| Amgen INC. | $78.13 | 2025 | Otezla, Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.61 | 2025 | Jardiance |
| Dexcom, INC. | $56.87 | 2024-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $56.57 | 2024-2025 | Mounjaro, Zepbound |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $47.55 | 2025 | Caplyta |
| Novo Nordisk INC | $43.62 | 2025 | Wegovy |
| Ucb, INC. | $37.26 | 2025 | Bimzelx |
| Astrazeneca Pharmaceuticals LP | $33.04 | 2025 | Airsupra |
| Eisai INC. | $28.56 | 2025 | |
| Novartis Pharmaceuticals Corporation | $23.48 | 2025 | |
| Dynavax Technologies Corporation | $19.18 | 2025 | Heplisav-B |
| Pfizer INC. | $16.97 | 2025 | |
| Organon LLC | $16.27 | 2025 | Nexplanon |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cipher Pharmaceuticals US LLC | $15.95 | 2025 | Natroba, Spinosad |
| Sumitomo Pharma America, INC. | $0.79 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larry Hollar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.